VE-822: Potent ATR Inhibitor for Cancer Research and Radiosensitization

Executive Summary: VE-822 (SKU: B1383) is a highly selective ATR kinase inhibitor with an IC50 of 0.019 μM, enabling precise DNA damage response (DDR) disruption in cancer cells exposed to replication stress or double-strand breaks [APExBIO product page]. It is an optimized analog of VE-821, offering superior ATR selectivity and radiosensitization efficacy in preclinical models. VE-822 sensitizes p53- and K-Ras-mutant pancreatic ductal adenocarcinoma (PDAC) cells to radiotherapy and gemcitabine, while sparing normal tissues [Gemcitabine HCl Article]. The compound displays limited solubility, requiring DMSO and careful handling for in vitro and in vivo studies. Its validated role in DDR pathway research and combination therapy highlights VE-822 as a cornerstone for translational oncology (Sequiera et al., 2022).

Biological Rationale

ATR (ATM-Rad3-related) kinase is a master regulator of the cellular response to DNA replication stress and double-strand breaks (DSBs). ATR activation halts the cell cycle and initiates DNA repair, maintaining genomic stability [DOI]. Tumor cells, particularly those with mutations in TP53 or K-Ras, are highly dependent on ATR signaling to survive DNA damage induced by radiotherapy or chemotherapy. Inhibiting ATR exposes these cancer cells to unrepaired DNA lesions, promoting cell death. VE-822 was developed to selectively block ATR kinase activity, enabling researchers to dissect DDR signaling and evaluate radiosensitization strategies in models of pancreatic ductal adenocarcinoma (PDAC) [Related DDR Review]. This article expands upon prior reviews by providing a comprehensive, structured evidence dossier and updated integration guidance for translational workflows.

Mechanism of Action of VE-822

VE-822 is a small-molecule inhibitor with high specificity for ATR kinase, exhibiting an IC50 of 0.019 μM under standard in vitro kinase assay conditions (25°C, ATP 10 μM, substrate peptide, 30 min) [APExBIO]. Upon binding, VE-822 competitively inhibits the ATP-binding pocket of ATR, blocking its kinase activity. This prevents phosphorylation of downstream targets, such as Chk1 at Ser-345, a critical mediator of S/G2 DNA damage checkpoint activation. As a result, cells are unable to halt the cell cycle or repair DNA via homologous recombination, especially under genotoxic stress. In p53-deficient or mutant K-Ras-expressing PDAC cells, this leads to sustained DNA damage, mitotic catastrophe, and apoptosis [Mechanistic Roadmap Article]. This mechanistic insight clarifies and operationalizes findings from previous reviews by providing quantitative benchmarks and stepwise inhibition pathways.

Evidence & Benchmarks

• VE-822 inhibits ATR kinase activity with an IC50 of 0.019 μM in biochemical assays (buffer: 50 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 1 mM DTT, 10 μM ATP, 25°C, 30 min incubation) (APExBIO).
• VE-822 is >100-fold selective for ATR over related kinases ATM and DNA-PK at 1 μM, minimizing off-target effects (see selectivity profile table, manufacturer's technical sheet) (APExBIO).
• In murine PDAC xenograft models, oral administration of VE-822 at 60 mg/kg in combination with radiation and gemcitabine significantly prolongs tumor growth delay versus control (median delay: 20.2 vs. 9.1 days, p<0.01), with no increase in normal tissue toxicity (Sequiera et al., 2022).
• VE-822 treatment reduces homologous recombination repair efficiency, as measured by decreased RAD51 foci formation (48 hours post-irradiation, PDAC cell lines, 2 Gy radiation, immunofluorescence assay) (Radiosensitization Benchmark).
• In vitro, VE-822 induces persistent γH2AX foci (a marker of unrepaired DNA DSBs) in PDAC cells exposed to radiotherapy (4 Gy, 24–48h post-treatment, immunofluorescence quantification) (Workflow Guidance Article).

Applications, Limits & Misconceptions

VE-822 is extensively used for:

• Research on DDR pathway modulation in cancer cell lines and xenograft models.
• Sensitizing PDAC and other solid tumors (e.g., ovarian, colorectal) to radiotherapy and cytotoxic agents (notably gemcitabine).
• Dissecting the interplay between ATR signaling, homologous recombination, and cell cycle checkpoints.
• Validating iPSC-based drug screening for personalized oncology, as described in Sequiera et al. (2022) (DOI).

For a broader discussion of strategic DDR disruption and iPSC-based integration, see Strategic Disruption of the DNA Damage Response, which this article updates by providing explicit, product-centered protocols and recent efficacy benchmarks.

Common Pitfalls or Misconceptions

• VE-822 is not a pan-PIKK inhibitor; it is highly selective for ATR and does not effectively inhibit ATM or DNA-PK at recommended concentrations.
• VE-822 is not soluble in aqueous buffers or ethanol; DMSO (≥50 mg/mL) is required for stock preparation, with warming and ultrasonic treatment recommended for complete dissolution.
• Prolonged storage at room temperature or repeated freeze-thaw cycles reduce VE-822 potency; short-term storage at -20°C is critical for maintaining activity.
• VE-822’s radiosensitizing effects are pronounced in p53- and K-Ras-mutant tumor models; normal cells with intact checkpoints are less affected, but off-target toxicity may occur at excessive dosages.
• VE-822 is not approved for clinical use; it is strictly for preclinical and translational research purposes.

Workflow Integration & Parameters

For optimal results:

• Stock Preparation: Dissolve VE-822 in DMSO at ≥50 mg/mL. Apply gentle warming (37–40°C) and ultrasonic agitation if needed. Avoid water or ethanol as solvents.
• Storage: Aliquot and store at -20°C. Use thawed aliquots within one week for best results.
• In Vitro Use: Typical working concentrations range from 0.01 to 2 μM. Maintain DMSO concentration <0.1% in cell culture media. Confirm ATR inhibition via Chk1 Ser-345 phosphorylation assays (Western blot, 2–4 hours post-treatment).
• In Vivo Use: Administer orally (gavage) at 60 mg/kg in murine models. Monitor for toxicity and weight loss. Combine with standard radiotherapy (2–4 Gy) and/or gemcitabine (100 mg/kg) for radiosensitization protocols.
• Readouts: Assess homologous recombination inhibition (RAD51 foci, 24–48h), persistent DNA damage (γH2AX), and tumor growth delay endpoints.

This workflow extends best practices outlined in Redefining Precision Oncology: Strategic Integration of VE-822 by emphasizing product-specific handling, storage, and benchmarking parameters for rapid translational deployment.

Conclusion & Outlook

VE-822, provided by APExBIO, is an advanced research tool enabling precise inhibition of ATR kinase and robust radiosensitization in preclinical cancer models (product B1383). Its validated selectivity, potent in vitro and in vivo activity, and compatibility with iPSC-based screening platforms have made it integral to translational DDR research and personalized oncology. Ongoing studies continue to refine its dosing, combinatorial regimens, and biomarker readouts—accelerating progress in the rational design of chemoradiotherapy sensitizers for pancreatic and other challenging malignancies (Sequiera et al., 2022). Researchers are encouraged to leverage established protocols, benchmark their workflows, and consult the VE-822 product page for technical updates and detailed usage guidelines.